Journal of Hepatology
Volume 48 , Pages S104-S112 , 2008

Non-alcoholic fatty liver disease: The mist gradually clears

  • Nimantha Mark Wilfred de Alwis
    • ,
  • Christopher Paul Day

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: School of Clinical Medical Sciences, Floor 4 William Leech Building, The Medical School, Framington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Tel.: +44 191 222 7043; fax: +44 191 222 0723.

References 

  1. Bedogni G, Miglioli L, Masutti F, Tiribelli C. Prevalence and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44–52
  2. Browning JS, Szczepaniak LS, Dobbins LS, Nuremberg R, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395
  3. Nomura H, Kashiwaqi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa Japan. Jpn J Med. 1988;27:142–149
  4. Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce L, Tiribelli C, et al. Incidence and natural course of fatty liver in the general population: The Dionysos Study. Hepatology. 2007;46:1387–1391
  5. Neuschwander-Tetri B, Caldwell S. Non alcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202–1219
  6. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in patients undergoing bariatric surgery. J Hepatol. 2006;45:600–606
  7. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106–1110
  8. Cheung P, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, et al. The impact of fat distribution on the severity of non-alcoholic fatty liver disease and the metabolic syndrome. Hepatology. 2007;46:1091–1100
  9. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relation between carotid artery wall thickness and liver histology in subjects with non-alcoholic fatty liver disease. Diabetes Care. 2006;29:1325–1330
  10. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease among Type 2 diabetic patients. Diabetes Care. 2007;30:1212–1218
  11. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Non-alcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917–923
  12. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci M, Saviano M, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow up in an Italian population. Dig Dis Sci. 1997;42:1428–1432
  13. Tominaga K, Kurata J, Chen Y, Fujimoto E, Miyagawa S, Abe I, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci. 1995;40:2002–2009
  14. Molleston J, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol. 2002;97:2460–2462
  15. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873
  16. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375–378
  17. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–689
  18. Nair S, Mason A, Eason J, Loss G, Perillo R. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology. 2002;36:150–155
  19. Calle E, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625–1638
  20. McCullough A. The clinical features, diagnosis and natural history of non-alcoholic fatty liver disease. Clin Liver Dis. 2004;8:521–533
  21. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121
  22. De Alwis N, Day CP. Genetics of alcoholic liver disease and non-alcoholic fatty liver disease. Semin Liver Dis. 2007;27:44–54
  23. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Faga E, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in non-alcoholic steatohepatitis. Hepatology. 2003;37:909–916
  24. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. Long term nutritional intake and the risk of non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007;47:711–717
  25. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108–111
  26. Dixon J, Bhathal P, O’Brian P. Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100
  27. Suzuki A, Angulo P, St Sauver J, Muto A, Okada T, Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol. 2007;102:1912–1919
  28. De Alwis N, Day CP. Genes and non-alcoholic fatty liver disease. Curr Diab Rep, in press.
  29. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in nondiabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22:1354–1358
  30. Fracanzani A, Burdick L, Raselli L, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in non-alcoholic fatty liver disease. Am J Med. 2008;121:72–78
  31. Schwimmer J, Deutsch R, Behling C, Lavine J. Fatty liver as a determinant of atherosclerosis. Hepatology. 2005;42:610A
  32. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day CP. Non-alcoholic fatty liver disease is independantly associated with an increased prevalence of Chronic kidney disease and proliferative/laser treated retinopathy in type 2 diabetic patients. Diabetologia, Epub ahead of print, doi:10.1007/s00125-007-0897-4.
  33. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–240
  34. Schwimmer J, Hhorram O, Chiu V, Schwimmer W. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril. 2005;83:494–497
  35. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, et al. Non-alcoholic fatty Liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47:412–417
  36. Setji T, Holland N, Sanders L, Pereira K, Diehl A, Brown A. Non-alcoholic steatohepatitis and non-alcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1741–1747
  37. Volk R, Somers V. Obesity related cardiovascular disease: implications of obstructive sleep apnea. Diabet Obes Met. 2005;8:250–260
  38. Tanne F, Gagnadoux F, Chazouilleres O, Fleury B, Wendum D, Lasnier E, et al. Chronic liver injury during obstructive sleep apnea. Hepatology. 2005;41:1290–1296
  39. Skelly M, James P, Ryder S. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35:195–199
  40. Pendino G, Mariano A, Surace P, Caserta C, Fiorello M, Amante A, et al. Prevalence and etiology of altered liver tests: a population based survey in a Mediterranean town. Hepatology. 2005;41:1151–1159
  41. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292
  42. Javor E, Ghany M, Cochran E, Oral E, DePaoli A, Premkumar A, et al. Leptin reverses non-alcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005;41:753–760
  43. Tanoli T, Tue P, Yablonskiy D, Schonfeld G. Fatty Liver in familial hypobetalipoproeteinaemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res. 2004;45:941–947
  44. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons. J Hepatol. 2007;46:549–552
  45. Bugianesi E, Manzini P, D’Antico S, Vanni E, Longo F, Leone N, et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepatology. 2004;39:179–187
  46. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2004;90:1316–1320
  47. Loria P, Carulli N, Lonardo A. The prevalence of autoantibodies and autoimmune hepatitis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2005;100:1200–1201
  48. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology. 2002;123:745–750
  49. Cox I, Sharif A, Cobbold J, Thomas H, Taylor-Robinson S. Current and Future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. World J Gastroenterol. 2006;12:4773–4783
  50. Yoneda M, Fujita K, Inamori M, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56:1330–1331
  51. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut. 2006;55:1650–1660
  52. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a non-invasive system that accurately identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854
  53. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713
  54. Guha I, Parkes J, Roderick P, Chattopadhay D, Cross R, Harris S, et al. Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers. Hepatology. 2007;47:455–460
  55. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in non-alcoholic fatty liver disease. Hepatology. 2006;44:27–33
  56. Day CP. From fat to inflammation. Gastroenterology. 2006;130:207–210
  57. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut. 2007;56:1760–1769
  58. Westerbacka J, Lammi K, Hakkinen AAR, Salminen I, Aro A, Yki-Jarvinen H. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab. 2005;90:2804–2809
  59. Ueno T, Sugawara S, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–110
  60. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharm Ther. 2004;20:623–628
  61. Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis (NASH). Dig Dis Sci. 2007;52:2512–2519
  62. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  63. Gary-Bobo M, Elachouri G, Galla J, Janiak P, Marini P, Ravinet-Trillou C, et al. Rimonabant reduces obesity associated hepatic steatosis and features of the metabolic syndrome in obese Zucker fa/fa Rats. Hepatology. 2007;46:122–129
  64. Teixeira-Clerc F, Julien B, Grenard P, Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006;12:671–676
  65. Dixon J, Bhathal P, Hughes N, O’Brien P. Improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647–1654
  66. Klein S, Mittendorfer B, Eagon C, Patterson B, Grant L, Feirt N, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with non-alcoholic fatty liver disease. Gastroenterology. 2006;130:1564–1572
  67. Adachi M, Osawa Y, Uchinami H, Kitamura T, Accili D, Brenner D. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology. 2007;132:1434–1446
  68. Juurinen L, Tiikkainen M, Hakkinen A, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;292:E829–E835
  69. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol. 2005;100:1082–1090
  70. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122:1924–1940
  71. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307
  72. Singh S, Loke Y, Furberg C. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. J Am Med Ass. 2007;298:1189–1195
  73. Lincoff M, Wolski K, Nicholls S, Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. J Am Med Ass. 2007;298:1180–1188
  74. Lutchman G, Modi A, Kleiner D, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with non-alcoholic steatohepatitis. Hepatology. 2007;46:424–429
  75. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPAR alpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004;39:1286–1296
  76. Laurin J, Lindor K, Crippin J, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464–1467
  77. Browning J. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 2006;44:466–471
  78. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007;45:1375–1381
  79. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensinogen II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222–1225
  80. Oben J, Roskams T, Yang S, Lin H, Sinelli N, Li Z, et al. Norepinephrine induces hepatic fibrosis in leptin deficient ob/ob mice. Biochem Biophys Res Commun. 2003;308:284–292
  81. Ichikawa Y. Comparative effects of Telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med. 2007;46:1331–1336
  82. Merat S, Malekzadeh R, Sohrabi M, Sotoudeh M, Rakhshani N, Sohrabpour AA, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double blind randomized controlled study. J Hepatol. 2003;38:414–418
  83. Abdelmalek M, Angulo P, Jorgensen R, Sylvestre P, Lindor K. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001;96:2711–2717
  84. Facchini F, Hua N, Stoohs R. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122:931–939
  85. Lavine J. Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734–738
  86. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and Vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485–2490
  87. Adams LA, Zein C, Angulo P, Lindor K. A pilot trial of pentoxyfylline in nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:2365–2368
  88. Satapathy S, Sakhuja P, Malhotra V, Sharma B, Sarin S. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:634–638
  89. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith R, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137–1140
  90. Lindor K, Kowdley K, Heathcote E, Harrison M, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of non alcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–778
  91. Dufour J, Oneta C, Gonvers J, Bihl F, Cerny A, Cereda JM, et al. Swiss Association for the Study of the Liver: randomized placebo controlled trial of ursodeoxycholic acid with Vitamin E in non-alcoholic steatohepatitis. Clin Gastroentrol Hepatol. 2006;4:1537–1543
  92. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7:363–373
  93. Ong J, Younossi Z, Reddy V, Price L, Gramlich T, Mayes J, et al. Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7:797–801

☆ C.P. Day is currently Chief investigator on a Sanofi-Aventis sponsored trial of rimonabant in non-alcoholic fatty liver disease. He has consultancies with Pfizer, UK Ltd., GlaxoSmithKline and Astellas with respect to developing therapies for NAFLD. He has received funding from ROCHE products UK to perform a study of orlistat in non-alcoholic fatty liver disease. He declares that he received funding from the Medical Research Council, UK, The Wellcome Trust, The Department of Health, UK and the Commonwealth Scholarship Commission.

PII: S0168-8278(08)00055-X

doi: 10.1016/j.jhep.2008.01.009

Journal of Hepatology
Volume 48 , Pages S104-S112 , 2008

Article Tools

* Image Usage & Resolution